<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935333</url>
  </required_header>
  <id_info>
    <org_study_id>IGX1-DTU-AM-21-03</org_study_id>
    <nct_id>NCT04935333</nct_id>
  </id_info>
  <brief_title>Accuracy of the Preoperative Molecular Diagnosis of Uterine Tumors by Liquid Biopsy</brief_title>
  <acronym>MYOSARCII</acronym>
  <official_title>Prospective, Observational and Multicenter Case-control Study to Evaluate the Precision of the Preoperative Molecular Diagnosis of Uterine Tumors by Liquid Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igenomix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Igenomix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of precise and non-invasive diagnostic methods is a priority in areas such as&#xD;
      gynaecology and oncology, and above all in improving the health of those patients with a&#xD;
      surgical indication for hysterectomy, laparoscopic or laparotomic myomectomy for diagnosis of&#xD;
      uterine tumours. Indeed, in the absence of an accurate and objective preoperative diagnostic&#xD;
      option, all patients with suspected benign tumours should be considered at risk for occult&#xD;
      leiomyosarcoma.&#xD;
&#xD;
      Recently, the concept of &quot;liquid biopsy&quot; has emerged as a minimally invasive alternative to&#xD;
      surgical biopsies for solid tumours with highly recurrent mutations, avoiding the sampling of&#xD;
      tumour tissue before and after treatment. Generally, the liquid biopsy is obtained by taking&#xD;
      a sample of blood or other body fluids, to provide tumour-specific information.&#xD;
&#xD;
      Based on these premises, a prospective, observational and multicentre case-control study is&#xD;
      proposed, the objective of which is to evaluate the diagnostic precision (sensitivity,&#xD;
      specificity, negative predictive value and positive predictive value) in the detection of&#xD;
      molecular differences by liquid biopsy in patients with suspected myometrial tumour&#xD;
      (leiomyoma / leiomyosarcoma).&#xD;
&#xD;
      Depending on the results of these analysis, the application of this technology could allow&#xD;
      the differential diagnosis of the tumour in a non-invasive and objective way, as well as the&#xD;
      development of biomarkers and effective targeted therapies in the treatment of&#xD;
      leiomyosarcomas. Consequently, we would also be increasing our knowledge of tumour biology&#xD;
      and associated pathologies in a clinical and therapeutic context.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, the concept of &quot;liquid biopsy&quot; has emerged as a minimally invasive alternative to&#xD;
      surgical biopsies. Generally, the liquid biopsy is obtained by taking a sample of blood or&#xD;
      other body fluids, to provide tumour-specific information.&#xD;
&#xD;
      The use of technologies such as high-throughput sequencing or Next Generation Sequencing&#xD;
      (NGS) could be an effective method for the detection of molecular differences from&#xD;
      circulating genetic material in peripheral blood of patients with suspected myometrial tumour&#xD;
      (leiomyoma / leiomyosarcoma), versus patients without tumour pathologies.&#xD;
&#xD;
      This is a prospective, multicentre, national biomedical case-control study aimed at patients&#xD;
      with a surgical indication for hysterectomy or myomectomy due to the diagnosis of myometrial&#xD;
      tumours (leiomyoma / leiomyosarcoma) according to standard clinical practice.&#xD;
&#xD;
      Once the study is approved by the Research Ethics Committee (CEI) of the Hospital, we will&#xD;
      proceed to the recruitment and selection of those patients who meet the inclusion criteria.&#xD;
&#xD;
      After obtaining informed consent, peripheral blood will be collected from the candidate&#xD;
      patient, prior to the surgery that the patient had already planned for medical indication in&#xD;
      accordance with the usual clinical practice or, in the case of control patients, during an&#xD;
      analysis or gynaecological consultation that was already planned to be performed by routine&#xD;
      clinical practice. These samples will be sent to the Igenomix Foundation laboratories for&#xD;
      molecular study.&#xD;
&#xD;
      Finally, and once both molecular and histological results are obtained, the precision of the&#xD;
      determination of the molecular results will be compared with the &quot;gold standard&quot; in the&#xD;
      diagnosis of myometrial tumours through two expert evaluators in pathological anatomy.&#xD;
&#xD;
      In this way, if the hypothesis raised is confirmed and the proposed objectives are achieved,&#xD;
      we would be demonstrating the viability of a minimally invasive and precise preoperative&#xD;
      diagnostic approach, based on the molecular characterization of leiomyoma and leiomyosarcoma.&#xD;
&#xD;
      When calculating the sample size for our study, we have considered the main objective, which&#xD;
      is the validation of the test, comparing it with the &quot;gold standard&quot; of pathological anatomy.&#xD;
      To calculate the sensitivity and specificity of the test, we would need a minimum of 200 LMS&#xD;
      samples, 200 LM samples, and 200 control patient samples for validation.&#xD;
&#xD;
      It is intended to establish a cut-off point with a preliminary analysis in the first 30&#xD;
      patients (10 first patients from each group), in which the laboratory data are combined with&#xD;
      those derived from the Pathological Anatomy (Gold Standard).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic precision of uterine tumours at molecular level</measure>
    <time_frame>25 months</time_frame>
    <description>Sensitivity, specificity, negative predictive value and positive predictive value of the molecular diagnosis of uterine tumours by liquid biopsy as a preoperative diagnosis, using pathological diagnosis as a &quot;gold standard&quot; to validate the molecular diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concordance of Circulating tumour DNA / RNA versus DNA / RNA in tumour</measure>
    <time_frame>25 months</time_frame>
    <description>Determine the concordance of circulating tumour DNA / RNA in plasma (ctRNA / ctDNA) versus the contribution of tumour tissue DNA / RNA in determining the diagnosis and histological subtype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-observer variability</measure>
    <time_frame>25 months</time_frame>
    <description>Inter-observer variability in determining the histological diagnosis of uterine tumours in the analysis performed by pathologists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Circulating tumour DNA / RNA profile for oncological outcome</measure>
    <time_frame>25 months</time_frame>
    <description>Contribution of the plasma circulating tumour DNA / RNA profile (ctRNA / ctDNA) in determining the oncological outcome (survival, disease-free interval)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Leiomyoma, Uterine</condition>
  <condition>Leiomyosarcoma Uterus</condition>
  <arm_group>
    <arm_group_label>Leiomyoma samples</arm_group_label>
    <description>Leiomyoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leiomyosarcoma samples</arm_group_label>
    <description>Leiomyosarcoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control samples</arm_group_label>
    <description>Peripheral blood samples obtained from women between 18 and 80 years without suspected myometrial tumour</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of Leiomyoma samples</intervention_name>
    <description>Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.&#xD;
A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis.</description>
    <arm_group_label>Leiomyoma samples</arm_group_label>
    <other_name>Obtainment of blood sample (peripheral blood) and tumour tissue sample</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of Leiomyosarcoma samples</intervention_name>
    <description>Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.&#xD;
A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis.</description>
    <arm_group_label>Leiomyosarcoma samples</arm_group_label>
    <other_name>Obtainment of blood sample (peripheral blood) and tumour tissue sample</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of control samples</intervention_name>
    <description>Peripheral blood will be collected during an analysis or gynaecological consultation already planned by routine clinical practice. The sample will be sent to Igenomix for molecular analysis.</description>
    <arm_group_label>Control samples</arm_group_label>
    <other_name>Obtainment of blood sample (peripheral blood)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples to provide tumour-specific information from the circulating tumour cells (CTC)&#xD;
      and or free tumour DNA / RNA (ctDNA / ctRNA) present in peripheral blood.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women between 18 and 80 years old and with a body mass index (BMI) of 18.5-40.0 kg / m2,&#xD;
        with suspected myometrial tumour (leiomyoma / leiomyosarcoma) based on clinical symptoms&#xD;
        and imaging diagnosis, will be evaluated in their referral centre, verifying that they meet&#xD;
        the inclusion / exclusion criteria to participate in the study. Women with the same age and&#xD;
        BMI but without a uterine tumour will be used as control patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who voluntarily sign the informed consent approved by the Research Ethics&#xD;
             Committee (CEI) after having been duly informed of the nature of the study, before&#xD;
             carrying out any test related to it, knowing the potential risks, benefits and&#xD;
             discomforts derived from their participation. Participants should be informed that&#xD;
             they may leave the study at any time, without this entailing any consequence for their&#xD;
             subsequent medical care.&#xD;
&#xD;
          -  BMI = 18.5-40 kg / m2&#xD;
&#xD;
          -  Age = 18-80 years&#xD;
&#xD;
          -  Surgical indication according to usual clinical practice, due to suspicion of a tumour&#xD;
             mass in the uterus, either primary (stages I-IV) or recurrence, but without prior&#xD;
             chemotherapy or radiotherapy (at the time of primary diagnosis or prior to recurrence)&#xD;
             .&#xD;
&#xD;
          -  Note: Control patients will have the same inclusion criteria for BMI and age but&#xD;
             without uterine tumour pathology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have participated in a clinical trial during the last 30 days unless it&#xD;
             is approved by the sponsor as it does not interfere with the current study.&#xD;
&#xD;
          -  Patients who have received chemotherapy or radiotherapy before taking the sample (in&#xD;
             case of recurrence).&#xD;
&#xD;
          -  Pregnant patients before or during the duration of the study.&#xD;
&#xD;
          -  Existence of serious or uncontrolled bacterial, fungal, or viral infections (type HPV,&#xD;
             HIV, hepatitis) that, in the opinion of the principal investigator, could interfere&#xD;
             with the participation of the patient in the study or in the evaluation of the study&#xD;
             results.&#xD;
&#xD;
          -  Any disease or medical condition that is unstable or may jeopardize patient safety and&#xD;
             compliance in the study. For example: patients with an active history of other&#xD;
             malignant tumours.&#xD;
&#xD;
          -  Psychological, family, sociological or geographical situations that do not allow&#xD;
             compliance with the protocol or the signing of informed consent.&#xD;
&#xD;
          -  Patients vaccinated with mRNA vaccines in the week before surgery.&#xD;
&#xD;
          -  Note: Control patients will have the same exclusion criteria as patients with tumour&#xD;
             pathology&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Simón, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Igenomix</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aymara Mas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Igenomix Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Gómez, BSc, MSc</last_name>
    <phone>+34 963905310</phone>
    <email>carlos.gomez@igenomix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L´Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Manuel Martínez, MD</last_name>
      <phone>+34 932 60 75 00</phone>
      <email>jmartinezgar@bellvitgehospital.cat</email>
    </contact>
    <contact_backup>
      <last_name>Sergi Fernández, MD</last_name>
      <phone>+34 932 60 75 00</phone>
      <email>sergi.sfg@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Son LLàtzer de Mallorca</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Reyes, MD</last_name>
      <phone>+34 871 20 20 00</phone>
      <email>areyes1@hsll.es</email>
    </contact>
    <contact_backup>
      <last_name>Cristina Martínez, MD</last_name>
      <phone>+34 871 20 20 00</phone>
      <email>mcmartinez@hsll.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Insular de Las Palmas</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Las Palmas</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Andújar, MD</last_name>
      <phone>+34 928 44 40 00</phone>
      <email>mandsan@gobiernodecanarias.org</email>
    </contact>
    <contact_backup>
      <last_name>Octavio Arencibia, MD</last_name>
      <phone>+34 928 44 40 00</phone>
      <email>octavaren@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Belén Martín, MD</last_name>
      <phone>+34 916 83 93 60</phone>
      <email>belenmsalamanca@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tirso Pérez, MD</last_name>
      <phone>+34 911 91 60 00</phone>
      <email>tirsoperezmedina@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Augusto Pereira, MD</last_name>
      <phone>+34 911 91 60 00</phone>
      <email>augusto.pereira@salud.madrid.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Cartagena</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastián Ortiz, MD</last_name>
      <phone>+34 968 12 86 00</phone>
      <email>sortizreina@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Carlos Muruzabal, MD</last_name>
      <phone>+34 848 42 22 22</phone>
      <phone_ext>59958</phone_ext>
      <email>jc.muruzabal.torquemada@navarra.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria José Román, MD</last_name>
      <phone>+34 965 93 30 00</phone>
      <email>mjromangine@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berta Díaz, MD</last_name>
      <phone>+34 932 27 54 00</phone>
      <email>bertadiazfeijoo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar Parc Salut</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gemma Mancebo, MD</last_name>
      <phone>+34 932 48 30 00</phone>
      <email>gemmamancebom@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de León</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tatiana Cuesta, MD</last_name>
      <phone>+34 987 23 74 00</phone>
      <email>tguardio@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital MD Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier De Santiago, MD</last_name>
      <phone>+34 912 77 72 20</phone>
      <email>jsantiagog@hotmail.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Iacoponi, MD</last_name>
      <phone>+34 914 52 19 00</phone>
      <email>saraiacoponi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Blanca Gil, MD</last_name>
      <phone>+34 913 90 80 00</phone>
      <email>blancalabacin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Alvaro Tejerizo, MD</last_name>
      <phone>+34 913 90 80 00</phone>
      <email>tejerizo@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca de Murcia</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aníbal Nieto, MD</last_name>
      <phone>+34 968 36 95 00</phone>
      <email>anibal.nieto@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesús Jimenez, MD</last_name>
      <phone>+34 951 29 00 00</phone>
      <email>jjimenezme35426@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Márquez, MD</last_name>
      <phone>+34 955 00 80 00</phone>
      <email>fmarquezma@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud de Toledo</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Rojas, MD</last_name>
      <phone>+34 925 26 61 00</phone>
      <email>sararjsrz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aymara Mas, PhD</last_name>
      <phone>+34 961 97 35 00</phone>
      <email>amas@incliva.es</email>
    </contact>
    <contact_backup>
      <last_name>Octavio Burgues, MD</last_name>
      <phone>+34 961 97 35 00</phone>
      <email>octavioburgues@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Gilabert, MD</last_name>
      <phone>+34 963 13 18 00</phone>
      <email>juangilaeste@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Aghababyan, MD</last_name>
      <phone>+34 963 13 18 00</phone>
      <email>dra.kristina.agababyan@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Domingo, MD</last_name>
      <phone>+34 961 24 43 50</phone>
      <email>santiago.domingo.delpozo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Javier Monleón, MD</last_name>
      <phone>+34 961 24 43 50</phone>
      <email>monlesancho@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leiomyoma (LM)</keyword>
  <keyword>Leiomyosarcoma (LMS)</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <keyword>Circulating tumour cells (CTC)</keyword>
  <keyword>Plasma cell-free RNA (cfRNA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

